6:37 PM
 | 
Jan 10, 2014
 |  BC Extra  |  Company News

Alnylam provides pipeline update

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) provided a pipeline update and said it expects to have six to seven programs in clinical development by YE15, exceeding the goals set in the company's original "Alnylam 5x15" plan. The company said it expects at least two programs in Phase III and...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >